| scholarly article | Q13442814 |
| P356 | DOI | 10.18632/ONCOTARGET.6685 |
| P8608 | Fatcat ID | release_amxfl35xkvcafhvjc3ou7k2vbi |
| P932 | PMC publication ID | 4868702 |
| P698 | PubMed publication ID | 26701728 |
| P5875 | ResearchGate publication ID | 288000802 |
| P50 | author | Elías Campo | Q5830202 |
| Dolors Colomer | Q43096016 | ||
| Gaël Roué | Q48337597 | ||
| Sílvia Xargay-Torrent | Q55445112 | ||
| Guillem Clot | Q55445114 | ||
| Marta Aymerich | Q60651570 | ||
| Marçal Pastor-Anglada | Q85787121 | ||
| P2093 | author name string | Laia Rosich | |
| Magda Pinyol | |||
| Armando López-Guillermo | |||
| Patricia Pérez-Galán | |||
| Arnau Montraveta | |||
| Mónica López-Guerra | |||
| Neus Villamor | |||
| Laura Jiménez | |||
| Jocabed Roldán | |||
| Eriong Lee-Vergés | |||
| Sandra Cabezas | |||
| Cristina Arimany-Nardí | |||
| P2860 | cites work | Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites | Q27011795 |
| Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia | Q28255147 | ||
| Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia | Q29614659 | ||
| The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. | Q30395427 | ||
| Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group | Q33396737 | ||
| Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group | Q33402713 | ||
| A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma | Q33418456 | ||
| Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL | Q33714712 | ||
| CD69 and regulation of the immune function | Q33721814 | ||
| Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells | Q33749652 | ||
| SF3B1 and other novel cancer genes in chronic lymphocytic leukemia | Q34093678 | ||
| Bendamustine: mechanism of action and clinical data. | Q34169315 | ||
| Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. | Q34172063 | ||
| The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia | Q34542102 | ||
| Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. | Q34586659 | ||
| Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling | Q34599670 | ||
| The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia | Q34923824 | ||
| The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications | Q35029409 | ||
| CD69 is the crucial regulator of intestinal inflammation: a new target molecule for IBD treatment? | Q35155979 | ||
| Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial | Q35560022 | ||
| The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. | Q35583403 | ||
| CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. | Q35717883 | ||
| Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo | Q35781372 | ||
| Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
| Initial treatment of CLL: integrating biology and functional status | Q36219647 | ||
| Molecular pathogenesis of chronic lymphocytic leukemia | Q36290321 | ||
| Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study | Q36883352 | ||
| Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics | Q36998431 | ||
| From pathogenesis to treatment of chronic lymphocytic leukaemia | Q37643423 | ||
| Update on therapy of chronic lymphocytic leukemia | Q37659071 | ||
| Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma | Q37718466 | ||
| Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity | Q37870438 | ||
| Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells | Q38920650 | ||
| The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia | Q39180275 | ||
| Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells | Q39328617 | ||
| Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance | Q39798268 | ||
| Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity | Q42401591 | ||
| Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. | Q42627572 | ||
| The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells | Q42705821 | ||
| The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells | Q42924738 | ||
| In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia | Q44161643 | ||
| Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. | Q46044632 | ||
| Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. | Q51979921 | ||
| Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. | Q53578680 | ||
| Renal human organic anion transporter 3 increases the susceptibility of lymphoma cells to bendamustine uptake. | Q53670141 | ||
| Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells. | Q54333325 | ||
| Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. | Q55056539 | ||
| Non-coding recurrent mutations in chronic lymphocytic leukaemia | Q56996904 | ||
| ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia | Q58042037 | ||
| The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells | Q72768300 | ||
| CD69 expression in B-cell chronic lymphocytic leukemia: a new prognostic marker ? | Q74452999 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bendamustine | Q425745 |
| lymphocyte | Q715347 | ||
| ibrutinib | Q5984881 | ||
| P304 | page(s) | 5507-5520 | |
| P577 | publication date | 2016-02-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia | |
| P478 | volume | 7 |
Search more.